Tresperimus: A new agent for transplant tolerance induction

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1381-1386

  Simpson, D ^a  

^a NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

Graft versus host disease; Immunosuppression; Tolerance; Transplant; Tresperimus

Indexed keywords

15 DEOXYSPERGUALIN; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD40 ANTIGEN; CHAPERONE; CYCLOSPORIN; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHYLPREDNISOLONE; SODIUM CHLORIDE; TRESPERIMUS; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL INTERACTION; CELL STIMULATION; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSOL; DENDRITIC CELL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; FLUSHING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEART TRANSPLANTATION; HUMAN; LETHARGY; LEUKEMIA; LYMPHOCYTE ACTIVATION; MOUTH DISEASE; MULTICENTER STUDY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ORTHOSTATIC HYPOTENSION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RAT; SHORT COURSE THERAPY; SKIN TRANSPLANTATION; T LYMPHOCYTE; VOMITING;

ANIMALS; CARBAMATES; GRAFT VS HOST DISEASE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAXIMUM TOLERATED DOSE; TRANSPLANTATION TOLERANCE;

EID: 0034936117     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1381     Document Type: Article

References (36)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Improved graft survival after renal transplantation in the United States, 1988 to 1996 [letter]
3. Graft tolerance: A duel of two signals
4. Anergic T cells inhibit the antigen-presenting function of dendritic cells
5. Synthesis and antitumor activity of spergualin analogues. II. Chemical modification of the spermidine moiety
6. A new antitumor antibiotic, spergualin: Isolation and antitumor
7. Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety
8. Phase I study of NKT-01
9. Suppression of humoral immunity in mice by spergualin
10. Prolongation of rat heart allograft survival by 15-deoxyspergualin
11. LF 08-0299 induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model
12. Tresperimus. LF 080299
13. Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells
14. The role of molecular chaperones in protein transport into the mammalian endoplasmic reticulum
15. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules
16. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation
17. Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues
18. In vivo inhibition of NF-κB in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis
19. Deoxyspergualin inhibits kappa light chain expression in 70Z/ 3 pre-B cells by blocking lipopolysaccharide-induced NF-κB activation
20. RelB is essential for the development of myeloid-related CD8α- dendritic cells but not of lymphoid-related CD8α+ dendritic cells
21. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction
22. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells
23. In vivo effects of the immuno-suppressant 15-deoxyspergualin on hematopoiesis in murine allogeneic bone marrow chimeras. Its thrombopoietic activity and reversal of adverse effects with granulocyte erythropoietin
24. Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats
25. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
26. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
27. The immunopharmacology of immunosuppression by 15-deoxyspergualin
28. Involvement of semicarbazide-sensitive amine oxidase in tresperimus metabolism in human and in rat
29. PhaseI/II evaluation of intravenous Tresperimus (LF 08-0299) and methylprednisolone as first line therapy for acute graft versus host disease
30. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients
31. Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients
32. Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection
33. 15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease after allogeneic bone marrow transplantation
34. Deoxyspergualin: Clinical experience
35. Deoxyspergualin: Phase I clinical, immunologic and pharmacokinetic study
36. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety